Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

2025

Does the timing of rituximab introduction in the treatment of diffuse large B-cell non-Hodgkin lymphoma affect progression-free survival?

INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is the most prevalent subtype of non-Hodgkin lymphoma. It behaves aggressively, and standard treatment is based on the R-CHOP regimen. Adding rituximab to the protocol has demonstrated clinical benefit, but the impact of the timing of its introduction remains unclear....

Miguel Roxo Veloso Franciosi, D. Borducchi, V. Mauad · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.